Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Pain, Postoperative 31Breast Neoplasms 24Agnosia 11Pain 10Lung Neoplasms 10Leiomyoma 7Pancreatic Neoplasms 5Neoplasms 5Prostatic Neoplasms 4Rectal Neoplasms 3Neuralgia 3Hot Flashes 3Colorectal Neoplasms 3Colonic Neoplasms 3Thyroid Nodule 2Thyroid Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neuroma 2Lymphedema 2Liver Neoplasms 2Kidney Neoplasms 2Ileus 2Hyperparathyroidism 2Goiter 2Digestive System Diseases 2Chronic Pain 2Breast Cancer Female 2Brain Neoplasms 2Adenomyosis 2Abdominal Cancer 2

Interventions

Paclitaxel 1Oxaliplatin 1Bupivacaine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Peritoneal Cancer × Bupivacaine × Clear all
NCT03359811 2022-02-18

Four Quadrants Transverse Abdominus Plane (4Q-TAP) Block With Plain and Liposomal Bupivacaine vs. Thoracic Epidermal Analgesia (TEA) in Patients Undergoing Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) on an Enhanced Recovery Pathway

M.D. Anderson Cancer Center

Phase 3 Completed
75 enrolled 21 charts

Peritoneal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡